Is AIP a Buy? What to Consider in 2026
Short answer
The bull case for AIP (AIP) rests on AI and chiplet demand tailwind: As chips get more complex and shift toward multi-die chiplet designs, the interconnect fabric Arteris licenses becomes harder to build in-house and more valuable. Revenue (Q1 2026 quarterly) is ~$22.9 million, up ~39% year over year. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. Whether AIP is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Arteris sells the plumbing that connects the pieces of a modern chip. Its network-on-chip (NoC) interconnect IP, sold under names like FlexNoC, Ncore, and the newer FlexGen, sits between the CPU, GPU, memory, and accelerator blocks on a system-on-chip and manages how data moves between them. Chip designers license this IP rather than build it themselves, which saves engineering time on increasingly complex designs. Arteris makes money in two layers: up-front and recurring license fees (tracked as annual contract value, or ACV) plus per-unit royalties that accrue every time a customer ships a chip containing its IP. That royalty stream is why the company reports metrics like combined ACV plus royalties (around $92.8 million exiting Q1 2026, up 39% year over year) and remaining performance obligations (about $118 million) alongside GAAP revenue. Founded in 2003 and headquartered in Campbell, California, Arteris went public on Nasdaq in 2021 under the ticker AIP. Its IP has shipped in more than 4 billion devices, and its customer roster spans large semiconductor and technology names including AMD, NXP, and AI-chip startup Tenstorrent, across automotive, AI and machine learning, enterprise computing, and consumer markets. The AI and chiplet boom has raised demand for exactly the kind of high-bandwidth on-chip connectivity Arteris specializes in, and the 2025 launch of FlexGen (a smart, more automated NoC generator) plus the acquisition of hardware-security firm Cycuity broadened its footprint. The stock rose sharply over the trailing year, which lifted the valuation well ahead of current revenue.
What's the case for buying AIP?
1. AI and chiplet demand tailwind
As chips get more complex and shift toward multi-die chiplet designs, the interconnect fabric Arteris licenses becomes harder to build in-house and more valuable. AI accelerators, automotive processors, and data-center silicon all need high-bandwidth on-chip connectivity. This structural demand is the core reason the business has been growing near 40% on its combined contract-plus-royalty metric.
2. Recurring license plus royalty model
Arteris earns up-front and recurring license fees plus per-unit royalties that accrue for years as customers ship products containing its IP. Variable royalties reached roughly $7.9 million in Q1 2026, up about 67% year over year. Because royalties compound off a growing installed base already shipped in over 4 billion devices, past design wins can keep paying out well after the initial contract.
3. New products and blue-chip customers
The 2025 launch of FlexGen, its smart NoC generator, reached over 30 production deployments across 10 customers by year end, and the Cycuity acquisition added hardware-security capability. Named users include AMD, NXP, and Tenstorrent. Each new design win with a large chipmaker seeds a future royalty stream and deepens Arteris' role in customer roadmaps.
4. Path toward profitability
Arteris carries a very high gross margin (around 90%) but still runs operating and net losses as it invests in engineering and sales. Management guided full-year 2026 revenue to roughly $91 to $95 million with positive free cash flow, so the debate is how quickly the high-margin revenue base grows into the cost structure and turns the reported losses into sustained profit.
What are the risks to AIP?
Arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. Royalty revenue depends on customers actually shipping chips, so it is exposed to the semiconductor cycle and to design cancellations or delays. The customer base is concentrated among a relatively small number of large chipmakers, and it competes with far larger EDA and IP vendors such as Cadence and Synopsys, plus the risk that big customers build interconnect in-house. Ongoing stock-based compensation dilutes shareholders, and a planned CFO transition in 2026 adds some management-continuity uncertainty.
How is AIP valued? (as of July 2026)
Snapshot for AIP as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (Q1 2026 quarterly): ~$22.9 million, up ~39% year over year
- ACV plus royalties (exiting Q1 2026): ~$92.8 million, up ~39%
- Full-year 2026 revenue guidance: ~$91 to $95 million, with positive free cash flow
- Net income (trailing): ~negative (net loss; not yet GAAP profitable)
- Price-to-sales ratio: ~27x
- Market cap: ~$2.0 billion (stock ~$47 per share)
Figures are approximate and tied to the asOf date, so verify live numbers before acting. AIP trades on a high price-to-sales multiple with a negative P/E because it is still unprofitable, so traditional earnings multiples do not apply. The valuation prices in continued rapid growth in contracts and royalties, which means the figures matter most as a gauge of how much optimism is already reflected in the stock.
How do you decide if AIP is a buy?
Rather than asking whether AIP is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold AIP indirectly through an index or sector ETF before adding more.
For the full picture, see the AIP stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AIP against your real portfolio and see your actual exposure before deciding.
The bottom line on AIP
The bottom line: AIP's story right now is AI and chiplet demand tailwind, with revenue (q1 2026 quarterly) at ~$22.9 million, up ~39% year over year. If you believe that narrative continues, the call is about sizing AIP sensibly and checking overlap with what you own; if you doubt it (the risk: arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around AIP with Walnut
Use AIP as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is AIP a good stock to buy right now?
+
The case for AIP right now is AI and chiplet demand tailwind, with revenue (q1 2026 quarterly) at ~$22.9 million, up ~39% year over year. If you believe that thesis holds, AIP is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does AIP do?
+
Arteris sells the plumbing that connects the pieces of a modern chip.
What are the main risks of AIP?
+
Arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. Royalty revenue depends on customers actually shipping chips, so it is exposed to the semiconductor cycle and to design cancellations or delays. The customer base is concentrated among a relatively small number of large chipmakers, and it competes with far larger EDA and IP vendors such as Cadence and Synopsys, plus the risk that big customers build interconnect in-house. Ongoing stock-based compensation dilutes shareholders, and a planned CFO transition in 2026 adds some management-continuity uncertainty.
What company is AIP?
+
AIP is the Nasdaq ticker for Arteris, Inc., a semiconductor system IP company based in Campbell, California. It licenses network-on-chip (NoC) interconnect and related IP that chip designers use to connect the blocks inside a system-on-chip. Its technology has shipped in more than 4 billion devices across AI, automotive, and consumer markets.
Is AIP a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is rapid growth in contracts and royalties driven by AI and chiplet demand and a very high gross margin. The bear case is that the company is still unprofitable and trades at a rich price-to-sales multiple after a large run-up. Weigh both against your own portfolio.
How does Arteris make money?
+
Arteris earns money in two layers. First, it charges license fees for its network-on-chip and system IP, tracked as annual contract value (ACV). Second, it collects per-unit royalties each time a customer ships a chip containing that IP. The royalty stream compounds over time as more designs reach production, which is why the company reports combined ACV plus royalties alongside revenue.
Does AIP pay a dividend?
+
No. Arteris does not pay a dividend. It is a growth-stage, currently unprofitable company that reinvests in engineering, sales, and acquisitions rather than returning cash to shareholders. Any return from AIP would come from share-price movement rather than income, which matters if you are building a portfolio for current yield.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell AIP; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.